Q-omics provides the consensus-scored RIC3-DT profile across patient tissues and cancer cell-line models. RIC3-DT expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RIC3-DT is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RIC3-DT RNA expression shows 10,224 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UCS, KIRC, and SARC as cancer lineages where RIC3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIC3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIC3-DT survival associations across molecular data types. RIC3-DT RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIC3-DT RNA expression–survival associations across cancer types. High RIC3-DT expression shows unfavorable associations in MESO, PCPG, COAD and CHOL, but favorable associations in UCS and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for RIC3-DT RNA expression.
This table summarizes RIC3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RIC3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIC3-DT shows lower tumor expression in KIRC, KICH, UCEC, THCA and LUAD. The KIRC box plot shows higher RIC3-DT RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p < 0.001).
This table shows molecular features associated with RIC3-DT in patient tissues and cancer cell lines. In patient samples, RIC3-DT shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
